{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:25:38Z","timestamp":1793917538440,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039100"],"award-info":[{"award-number":["R01DA039100"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023581","name":"National Science Foundation Graduate Research Fellowship Program","doi-asserted-by":"publisher","award":["2041772"],"award-info":[{"award-number":["2041772"]}],"id":[{"id":"10.13039\/100023581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuropharm.2026.111131","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:03:38Z","timestamp":1785708218000},"page":"111131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual hypocretin receptor antagonism reduces oxycodone seeking and attenuates aberrant dopamine transporter function during abstinence"],"prefix":"10.1016","volume":"300","author":[{"given":"Kyle R.","family":"Samson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Bashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo A.","family":"Espa\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111131_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2022.100029","article-title":"Incubation of cocaine craving coincides with changes in dopamine terminal neurotransmission","volume":"3","author":"Alonso","year":"2022","journal-title":"Addict. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111131_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00213-020-05750-2","article-title":"A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse","volume":"238","author":"Bakhti-Suroosh","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111131_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pbb.2015.12.007","article-title":"The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats","volume":"142","author":"Bernosky-Smith","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111131_bib4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/adb.12553","article-title":"Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine","volume":"23","author":"Bernstein","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2026.111131_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2023.100104","article-title":"Hypocretin\/orexin receptor 1 knockdown in GABA or dopamine neurons in the ventral tegmental area differentially impact mesolimbic dopamine and motivation for cocaine","volume":"7","author":"Black","year":"2023","journal-title":"Addict. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111131_bib6","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s12035-018-1318-z","article-title":"Molecular adaptations in the rat dorsal striatum and hippocampus following abstinence-induced incubation of drug seeking after escalated oxycodone self-administration","volume":"56","author":"Blackwood","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111131_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neuroscience.2019.07.030","article-title":"Escalated oxycodone self-administration causes differential striatal mRNA expression of FGFs and IEGs following abstinence-associated incubation of oxycodone craving","volume":"415","author":"Blackwood","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111131_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.07.027","article-title":"Hypocretin receptor 1 involvement in cocaine-associated behavior: therapeutic potential and novel mechanistic insights","volume":"1731","author":"Brodnik","year":"2020","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111131_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00213-002-1030-5","article-title":"Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences","volume":"161","author":"Carroll","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111131_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0091-3057(02)01039-0","article-title":"Gender differences in the intravenous self-administration of mu opiate agonists","volume":"74","author":"Cicero","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2026.111131_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-025-02315-9","article-title":"Hypocretin receptor 1 blockade early in abstinence prevents incubation of cocaine seeking and normalizes dopamine transmission","author":"Clark","year":"2026","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.neuropharm.2026.111131_bib12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/s41386-019-0458-9","article-title":"Experimental design and analysis for consideration of sex as a biological variable","volume":"44","author":"Diester","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-010-2048-8","article-title":"Hypocretin 1\/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration","volume":"214","author":"Espa\u00f1a","year":"2011","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1460-9568.2009.07065.x","article-title":"The hypocretin\u2013orexin system regulates cocaine self\u2010administration via actions on the mesolimbic dopamine system","volume":"31","author":"Espa\u00f1a","year":"2010","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111131_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12946","article-title":"Intermittent self\u2010administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system","volume":"26","author":"Fragale","year":"2021","journal-title":"Addict. Biol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111131_bib16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","article-title":"The role of orexin-1 receptor signaling in demand for the opioid fentanyl","volume":"44","author":"Fragale","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111131_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70817","article-title":"Reporting and misreporting of sex differences in the biological sciences","volume":"10","author":"Garcia-Sifuentes","year":"2021","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addict. Biol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111131_bib19","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41386-021-01035-0","article-title":"Enhanced heroin self-administration and distinct dopamine adaptations in female rats","volume":"46","author":"George","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111131_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1127735","article-title":"Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats","volume":"14","author":"Illenberger","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111131_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41386-018-0191-9","article-title":"Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies","volume":"44","author":"Kamp","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00213-013-3148-z","article-title":"Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment","volume":"230","author":"Liu","year":"2013","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002130050979","article-title":"Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats","volume":"144","author":"Lynch","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2026.111131_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107906","article-title":"Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats","volume":"164","author":"Matzeu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111131_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146461","article-title":"Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil","volume":"1731","author":"Mohammadkhani","year":"2020","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1523\/JNEUROSCI.2761-05.2006","article-title":"Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine","volume":"26","author":"Narita","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111131_bib27","article-title":"The dual orexin\/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl","author":"O'Connor","year":"2020","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/adb.12323","article-title":"Individual differences in orexin\u2010 receptor modulation of motivation for the opioid remifentanil","volume":"22","author":"Porter-Stransky","year":"2017","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/cn500246j","article-title":"Hypocretin\/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1","volume":"6","author":"Prince","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111131_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.119","article-title":"Studying sex differences in rodent models of addictive behavior","volume":"1","author":"Radke","year":"2021","journal-title":"Curr. Protoc."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111131_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111131_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2026.110898","article-title":"Hypocretin receptor 1 blockade early in abstinence reduces future demand for cocaine","volume":"291","author":"Samels","year":"2026","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111131_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13241","article-title":"Intermittent access to oxycodone decreases dopamine uptake in the nucleus accumbens core during abstinence","volume":"27","author":"Samson","year":"2022","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111131_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/npp.2014.293","article-title":"Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats","volume":"40","author":"Schmeichel","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2026.111131_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.09.042","article-title":"PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users","volume":"579","author":"Shi","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3940(93)90360-W","article-title":"Chronic morphine alters dopamine transporter density in the rat brain: possible role in the mechanism of drug addiction","volume":"163","author":"Simantov","year":"1993","journal-title":"Neurosci. Lett."},{"issue":"21","key":"10.1016\/j.neuropharm.2026.111131_bib37","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00213-017-4709-3","article-title":"Role of hypocretin\/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats","volume":"234","author":"Simmons","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111131_bib38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1460-9568.2012.08013.x","article-title":"Orexin\/hypocretin 1 receptor antagonist reduces heroin self\u2010administration and cue\u2010induced heroin seeking","volume":"35","author":"Smith","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"24","key":"10.1016\/j.neuropharm.2026.111131_bib39","doi-asserted-by":"crossref","first-page":"9333","DOI":"10.1523\/JNEUROSCI.20-24-09333.2000","article-title":"Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine","volume":"20","author":"Thompson","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111131_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.03.019","article-title":"Male and female mice develop escalation of heroin intake and dependence following extended access","volume":"151","author":"Towers","year":"2019","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111131_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamapsychiatry.2022.1240","article-title":"Association of Drug cues and craving with drug use and relapse: a systematic review and meta-analysis","volume":"79","author":"Vafaie","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/lm.050187.119","article-title":"Acute ovarian hormone treatment in freely cycling female rats regulates distinct aspects of heroin seeking","volume":"27","author":"Vazquez","year":"2020","journal-title":"Learn. Mem."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","author":"Winrow","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2026.111131_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by Suvorexant\u2014A novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J. Neurogenet."},{"issue":"21","key":"10.1016\/j.neuropharm.2026.111131_bib45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/00029330-200611010-00007","article-title":"Changes of dopamine transporter function in striatum during acute morphine addiction and its abstinence in rhesus monkey","volume":"119","author":"Xiao","year":"2006","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-011-2454-6","article-title":"Availability of dopamine and serotonin transporters in opioid-dependent users\u2014a two-isotope SPECT study","volume":"220","author":"Yeh","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111131_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jneumeth.2011.03.001","article-title":"Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures","volume":"202","author":"Yorgason","year":"2011","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111131_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/adb.12271","article-title":"Comparison of striatal dopamine transporter levels in chronic heroin\u2010dependent and methamphetamine\u2010dependent subjects","volume":"22","author":"Yuan","year":"2017","journal-title":"Addict. Biol."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111131_bib49","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/npp.2012.37","article-title":"The motivation to self-administer is increased after a history of spiking brain levels of cocaine","volume":"37","author":"Zimmer","year":"2012","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:51:31Z","timestamp":1793915491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"alternative-id":["S0028390826003060"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111131","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual hypocretin receptor antagonism reduces oxycodone seeking and attenuates aberrant dopamine transporter function during abstinence","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111131"}}